| Active substance | Pembrolizumab – MK 3475 |
| Holder | MSD |
| Status | Closed |
| Indication | Advanced (unresectable or metastatic) melanoma in first line or after BRAF inhibitor |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 07/06/2016 |
Keytruda®
Last updated on 16/12/2020